The Apex Times
Above the Noise
Business Wire
BusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex TimesBusinessDisney reportedly offers $20 million for Character.AI’s IP as lawsuits swirl around chatbot self-harm claimsThe Apex TimesBusinessApple readies legal push against UK proposal to open iPhone tap-to-pay rules, with fees at the centerThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex TimesBusinessDisney reportedly offers $20 million for Character.AI’s IP as lawsuits swirl around chatbot self-harm claimsThe Apex TimesBusinessApple readies legal push against UK proposal to open iPhone tap-to-pay rules, with fees at the centerThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex TimesBusinessDisney reportedly offers $20 million for Character.AI’s IP as lawsuits swirl around chatbot self-harm claimsThe Apex TimesBusinessApple readies legal push against UK proposal to open iPhone tap-to-pay rules, with fees at the centerThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex TimesBusinessDisney reportedly offers $20 million for Character.AI’s IP as lawsuits swirl around chatbot self-harm claimsThe Apex TimesBusinessApple readies legal push against UK proposal to open iPhone tap-to-pay rules, with fees at the centerThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex Times
Back to front
24/7 Wall St. sets a $1,349.37 target for Eli Lilly, citing momentum in its GLP-1 franchise
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 1, 1:46 PM EDT

24/7 Wall St. sets a $1,349.37 target for Eli Lilly, citing momentum in its GLP-1 franchise

A market-news analysis argues that Eli Lilly’s growth outlook supports a double-digit upside case for its stock, projecting a 12.5% gain from a recent trading reference point.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Eli Lilly’s shares (NYSE: LLY) are drawing fresh attention from market analysts after 24/7 Wall St. published a price-target outlook that calls for double-digit upside. In the post dated July 1, 2026, the outlet assigned a 12.5% potential gain, pointing to a target price of $1,349.37 versus a referenced share price of $1,199.43.

The article frames its bullish case around what it calls Lilly’s “GLP-1 franchise,” referring to the company’s lineup of medicines built on glucagon-like peptide-1, a hormone pathway widely targeted to treat obesity and diabetes. The piece characterizes the franchise as “compounding faster,” suggesting accelerating value drivers behind the products rather than a flat trajectory.

24/7 Wall St. also rates Eli Lilly a “buy” and assigns a “90% confidence score.” The post presents these as part of its methodology, but it does not provide primary-source documentation such as regulatory updates, trial readouts, or company financial guidance to back the specific target figure in the excerpted material.

A key detail in the outlook is the magnitude of the implied upside. Using the outlet’s own arithmetic, the move from $1,199.43 to $1,349.37 represents an approximately 12.5% increase. The post does not specify a time horizon in the provided summary, nor does it break down what factors would need to change to realize the target.

While the argument centers on GLP-1 momentum, the post does not lay out specific drivers such as new product launches, label expansions, changes to pricing, or manufacturing capacity. It also does not cite particular numbers like revenue growth rates, profit margins, or prescription trends in the information provided here.

For investors tracking Eli Lilly, the practical question is how much of the thesis is tied to near-term catalysts versus longer-term expectations for demand and competitive positioning in the GLP-1 market. The GLP-1 category has been dominated by high-profile therapies, and companies in the space often see sentiment move on expectations for new indications, affordability dynamics, and durability of demand.

Still, the post leaves several items unclear. In the excerpted material available for review, there is no detailed discussion of Lilly’s latest earnings performance, forward guidance, cash flow, or backlog. There is also no explanation of risks such as trial outcomes, regulatory hurdles, competitive pressures, or payer restrictions. In other words, the upbeat price framing is presented, but the underlying evidence is not spelled out in the portion provided.

Looking ahead, what matters for readers is whether Lilly’s reported results and any future regulatory or clinical updates align with the faster “compounding” narrative described by 24/7 Wall St. The near-term watchpoints typically include quarterly financial disclosures, updates on demand for GLP-1 products, and any developments that could affect pricing or patient access, since those are the inputs that generally determine whether stock targets remain credible.

Why It Matters

  • Market-target updates can influence investor sentiment, especially for stocks closely tied to the GLP-1 obesity and diabetes category.
  • A bullish price target indicates optimism about product demand and longer-term growth expectations, even when the underlying evidence is not fully detailed in the excerpted material.
  • Readers may use the target as a benchmark for how optimistic analysts are, while still needing to verify the assumptions against Lilly’s disclosed fundamentals.
  • Because the post does not provide detailed company metrics in the available text, investors should treat the target as one perspective rather than a complete analysis of risks or catalysts.

Sources

Key Facts

  • 24/7 Wall St. set a price target for Eli Lilly of $1,349.37.
  • The post cites a referenced share price of $1,199.43, implying 12.5% upside to the target.
  • The outlet assigned Eli Lilly a “buy” rating.
  • The post included a “90% confidence score.”
  • The post’s rationale highlights Lilly’s “GLP-1 franchise” and describes it as “compounding faster.”
  • The content provided does not include a detailed breakdown of the specific financial or operational drivers behind the target.

Healthcare Related

24/7 Wall St. sets a $1,349.37 target for Eli Lilly, citing momentum in its GLP-1 franchise | The Apex Times